Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | RXRB | P28702 | 2/20 | 0.33 |
| ▸ | RXRG | P48443 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829782 | 0.84 | RAB9A (0.41) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL829589 | 0.81 | RXRA (0.43) | RXRARXRBRXRG | |
| SCHEMBL2396649 | 0.79 | SMN1; SMN2 (0.47) | RXRA | |
| SCHEMBL829839 | 0.78 | ALDH1A1 (0.46) | RXRARXRBRXRG | |
| SCHEMBL829696 | 0.77 | AURKA (0.38) | HDAC6HDAC3HDAC1HDAC2HCAR3 | |
| SCHEMBL830043 | 0.77 | ALDH1A1 (0.43) | HDAC6HDAC3HDAC1HDAC2RXRA | |
| SCHEMBL830231 | 0.76 | AURKA (0.40) | HDAC6HDAC3HDAC1HDAC2HCAR3 | |
| SCHEMBL11956667 | 0.75 | P4HTM (0.53) | — | |
| SCHEMBL2395760 | 0.75 | HCAR3 (0.53) | HCAR3 | |
| SCHEMBL11955422 | 0.74 | MEN1 (0.55) | RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143260-B2 | Tricyclic amine compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143260-B2 | Tricyclic amine compound | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20110288299-A1 | TRICYCLIC AMINE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110288299-A1 | TRICYCLIC AMINE COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288299-A1 | TRICYCLIC AMINE COMPOUND | RXRA, RXRB, NR2C2 | HDAC6 636/4885HDAC3 66/4885HDAC1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.